Objectives: To identify barriers to hydroxyurea adherence (negative beliefs, access, and/or recall barriers), and their relationship to adherence rates and health-related quality of life (HRQOL) among adolescents and young adults (AYA) with sickle cell disease (SCD). 
to different medications in patients with SCD, including hydroxyurea. 9 Furthermore, despite our current knowledge of barriers to hydroxyurea adherence, the relationship between hydroxyurea adherence barriers and HRQOL is poorly understood in AYA with SCD.
Engaging adolescents with SCD in self-management skill building, including adherence to hydroxyurea, could have long-term benefits. [16] [17] [18] Recent National Institute of Health guidelines recommend the use of hydroxyurea for SCD patients as young as 9 months of age, and optimizing hydroxyurea adherence throughout the lifespan is essential, particularly among adolescents and young adults (AYA).
Therefore, improving adherence to hydroxyurea among AYA with SCD could substantially improve HRQOL and health outcomes, and a better understanding of these adherence barriers represents a key strategy to improving hydroxyurea adherence in this population.
The objectives of this study are (i) to identify barriers to hydroxyurea adherence, such as negative beliefs, access, and/or recall barriers, among AYA with SCD using the Brief Medication Questionnaire (BMQ) 19 and (ii) to examine the relationship between hydroxyurea adherence barriers, adherence rates, and HRQOL scores. We hypothesized that barriers to hydroxyurea adherence are associated with poor adherence and poor HRQOL. 
| METHODS

| Participant enrollment
| Study measures
Using an electronic tablet, participants were asked to complete self-administered questionnaires including the BMQ, modified measures. All study measures were pretested with AYA to ensure interpretation of different scale items. Participants had no difficulty understanding the language or language used. Research staff was also available to answer any questions from participants during the study. All adherence measures were adapted to reflect SCD and hydroxyurea.
To evaluate barriers to hydroxyurea adherence over the past 7 days, we used the BMQ, which include questions focused on three domains: negative beliefs or motivational barriers, recall barriers, and access barriers. 19 Negative beliefs were present if participants reported that hydroxyurea either does not work for them at all or they do not know and/or if it bothers them in any way. Recall barriers were present if participants found it a little or a lot harder to remember to take their hydroxyurea doses. Access barriers were present if participants reported that it was a little or a lot harder for them to pay for hydroxyurea and/or to get refills on time.
We used ©MMAS-8 to evaluate adherence over the past day and 2 weeks separately. 20 
| Data collection
Two online platforms were used to complete study measures, REDCap for hydroxyurea adherence data, and the Assessment Center SM for PROMIS ® data. Initially, we used the REDCap platform to administer PROMIS ® assessments, which resulted in the loss of PROMIS ® data for three patients due to technical difficulties and instability of the platform. However, HRQOL assessments were subsequently collected through the PROMIS ® Assessment Center SM platform for the rest of the study. We also conducted a medical chart review to collect information on SCD-related clinical events, hydroxyurea (indication, dose, and duration of treatment), and select laboratory parameters at the time of enrollment, including hemoglobin (Hb), fetal hemoglobin (HbF), mean corpuscular volume (MCV), white blood cells (WBCs), and absolute neutrophil count (ANC).
| Statistical analysis
Descriptive statistics for categorical data are reported in frequencies and percentages. Nonparametric stringent statistics were used. Wilcoxon rank-sum test, Kruskal-Wallis test, chi-square, and Fisher's exact tests were performed to determine significant associations among variables.
Spearman's rho correlations (r s ) were calculated to examine the relationship between relevant continuous variables. All tests were two sided, and a P-value <.05 was considered statistically significant. Statistical analysis was conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
| RESULTS
| Patient characteristics
Thirty-four patients were enrolled in the study (median age 13. 
| Adherence barriers
In our cohort, participants reported barriers related to hydroxyurea, including negative beliefs or motivational barriers (n=11, 32%), recall barriers or forgetfulness (n=15, 44%), and access barriers such as paying for hydroxyurea and/or getting refills on time (n=11, 32%). Overall, the number of barriers to hydroxyurea adherence varied among participants: no barriers in 11/34 (32%), one barrier in 11/34 (32%), two barriers in 10/34 (29%), and three barriers in only 2/34 patients (6%).
There were no significant differences in the reported individual barriers or the total number of barriers to hydroxyurea adherence by age cohort (12-17 vs 18-22 years), sex (male vs female), or number of hospitalizations (0 vs 1-3 vs ≥4) (data not shown). 
| Adherence barriers and HRQOL
| Adherence barriers and rates
Adherence levels can range from 0 to 8 for the ©MMAS-8 and from 0 to Using ©MMAS-8, significantly more participants with moderate or high hydroxyurea adherence reported no access barriers, when compared to those with low adherence (100% vs 44%, P=.02) ( Table 3) .
Using VAS dose scale, significantly more participants with high hydroxyurea adherence (≥80%) reported no recall barriers, when compared to those with low adherence (<80%) (76% vs 35%, P=.01) ( Table 3) .
| Adherence barriers and laboratory markers
In a subanalysis of HbSS patients, we examined the relationship be- Participants who reported negative beliefs had significantly lower HbF% (P=.01) and MCV values (P=.03) but higher WBCs (P=.008), suggesting lower adherence levels (Table 4) . Similarly, participants with recall barriers had significantly lower MCV (P=.02) but higher WBCs (P=.02) and ANC (P=.04), indicating lower adherence to hydroxyurea (Table 4) . We found no significant differences in laboratory markers among participants by type of barrier reported (data not shown).
| DISCUSSION
Our study contributes to the emerging literature on hydroxyurea. A unique feature of our study is its focus on examining the frequency of barriers to hydroxyurea adherence using the BMQ, as reported by AYA with SCD rather than their caregivers. 9,10 Moreover, we evaluated the clinical utility of the BMQ by assessing the relationship of hydroxyurea adherence barriers to actual adherence rates and HRQOL.
We found that a significant number of our participants had challenges with hydroxyurea adherence related to negative beliefs, recall barriers, and/or access barriers. In addition, we found that patients with no or fewer barriers to hydroxyurea adherence were more likely to have higher adherence rates and better HRQOL. However, our small sample size and the relatively low statistical power limited our ability to examine some important relationships of potential significance, particularly among hydroxyurea adherence barriers, adherence rates, and HRQL scores.
Patients with SCD receiving hydroxyurea have better HRQOL compared to those who are not. 5, 28 In support of these findings, our group has previously reported better HRQOL scores in patients with higher hydroxyurea adherence rates, when compared to those with lower adherence. 13 In our study, we showed that patients on hydroxyurea with no recall barriers had better HRQOL and higher adherence rates by both recall tools (VAS dose and ©MMAS) and objective laboratory data. Given the nature of our cross-sectional study, we cannot determine the direction of the cause-and-effect relationship, if present, between recall barriers and HRQOL. Recall barrier to medication adherence, or forgetfulness, is the most common reason for low or nonadherence in the general population and in patients with SCD as well as other patient populations. 9, 29, 30 However, in AYA and other patients with SCD, poor executive functioning and/or other cognitive deficits may contribute further to recall barriers. Patients, parents, and physicians estimate a clinically meaningful T-score difference of 2-6 points using PROMIS ® measures. 31, 32 Therefore, although the differences in some of the HRQOL domain scores were not statistically significant in participants with or without hydroxyurea adherence barriers, these T-score differences (median 4, IQR 3-9 points) are considered clinically important for patients, parents, and physicians. Our inability to detect statistically significant differences for these domains could be related to our small sample size and the relatively low statistical power. Earlier studies have reported the inability to obtain hydroxyurea refills as another major barrier to adherence. 9, 10 In support of this, we found that a third of our AYA with SCD reported access barriers, in particular paying for their hydroxyurea and getting refills on time.
T A B L E 3 Barriers to hydroxyurea adherence and levels of adherence (N=34)
This could be related to lack of insurance coverage, high or unaffordable copay payments, and/or limited availability of some of the liquid formulation of hydroxyurea. These challenges are not unexpected in minority, low-income populations with common psychosocial problems. 3, 33, 34 We also found that almost all patients with high adherence levels had no access barriers, suggesting that overcoming access barriers could improve adherence rates. These findings indicate that, in patients with SCD, efforts to increase the availability of hydroxyurea and the ability to obtain refills could improve adherence to hydroxyurea.
Despite growing evidence to support the safety and efficacy of hydroxyurea in SCD, it is underutilized and adherence remains suboptimal. 4, [9] [10] [11] [12] 14, 15 Consistent with previous reports, 9, 10, 14, 35 our results
showed that a third of our AYA with SCD had negative beliefs and concerns about hydroxyurea. In addition, we found that patients with negative beliefs related to hydroxyurea had laboratory data suggestive of lower adherence rates. Haywood et al. 14 have reported that patients'
concerns about hydroxyurea may relate to the following: no perceived benefit, lack of knowledge, and side effects (eg, safety, reproductive effects, and carcinogenicity). However, in our study, we did not examine the specifics of or reasons behind patients' negative beliefs or motivational barriers.
Some limitations warrant discussion. First, our study was a crosssectional study with a small sample size, which may have limited our ability to find statistically significant relationships between some hydroxyurea adherence barriers, adherence rates, and HRQOL scores.
Future longitudinal studies with larger sample size are needed to further clarify these relationships. Second, this was a single institution study at a large urban hospital, and the barriers identified in this study may not be generalizable to other populations, such as AYAs living in a more rural setting. Third, we evaluated hydroxyurea adherence using self-report measures, which have some methodological limitations (eg, recall bias and over-reporting). 36 However, we supplemented our assessment of hydroxyurea adherence with surrogate laboratory markers to evaluate hydroxyurea adherence, which are commonly used to monitor hydroxyurea adherence in HbSS patients. 37, 38 In addition, a recent report from a panel of medication adherence research experts across the disease spectrum-assembled by the National Institute of Health Adherence Network-supported the use of self-report adherence measures, given their high specificity. 36 Future studies should also consider other objective measures hydroxyurea adherence, such as medication possession ratios and electronic pill bottles. 25 (14, 33) .01 16 (9, 29) 19 (14, 31) .38 15 (13, 27) 22 ( status and possible related challenges. A comprehensive adherence screening process could help to inform efforts to improve adherence among SCD patients receiving hydroxyurea, given the magnitude of different barriers, and to develop patient-centered adherence interventions that would be customized to individual patient needs.
Prospective intervention studies with larger sample size addressing adherence barriers related to negative beliefs, forgetfulness, access, and other actionable barriers could lead to higher adherence levels, and therefore improve HRQOL and other important clinical outcomes.
